Welcome to our dedicated page for Sellas Life Sciences Group news (Ticker: SLS), a resource for investors and traders seeking the latest updates and insights on Sellas Life Sciences Group stock.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on developing novel therapies for cancer, with a strong emphasis on acute myeloid leukemia (AML) and other hematologic malignancies. This news page aggregates company announcements, clinical updates, financial disclosures, and collaboration news related to SLS.
Readers can follow developments around SELLAS’ lead product candidate galinpepimut-S (GPS), a WT1-targeted peptide immunotherapy licensed from Memorial Sloan Kettering Cancer Center, which is being evaluated in the pivotal Phase 3 REGAL trial as a potential maintenance therapy in AML after second complete remission. News items include updates on the REGAL trial’s progress, Independent Data Monitoring Committee recommendations, and commentary from investigators and key opinion leaders.
The SLS news feed also covers SLS009 (tambiciclib), SELLAS’ highly selective CDK9 inhibitor. Articles highlight Phase 2 clinical data in relapsed or refractory AML with myelodysplastic syndrome-related changes (AML-MR) after prior venetoclax-based treatment, including reported response rates, survival outcomes, and safety findings for SLS009 in combination with azacitidine and venetoclax. Preclinical results in T-cell prolymphocytic leukemia (T-PLL) and mechanistic studies in AML cell lines are also featured in conference-related releases.
In addition to clinical and scientific news, this page includes corporate updates such as participation in investor conferences, warrant exercise transactions, and quarterly financial results as reported in press releases referenced by Form 8-K filings. Investors and followers of SLS can use this page to review the sequence of material events, from R&D days and conference presentations to financing activities and operational updates, in one organized stream of company-specific news.
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) announced a public offering of 7,220,217 shares of common stock at $2.77 per share, including warrants with the same exercise price. The offering, expected to raise $20 million prior to expenses, is anticipated to close on February 28, 2023. Cantor Fitzgerald & Co. is the sole book-running manager. All securities are being sold by SELLAS under a previously declared effective shelf registration. The company focuses on developing novel cancer therapies, with lead candidate GPS targeting various tumors.
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) announced an underwritten public offering of shares and warrants to purchase its common stock. All securities in this offering will be sold by the company, with Cantor Fitzgerald & Co. acting as the sole book-running manager. The offering is subject to market conditions, and its terms are yet to be finalized. This initiative is in accordance with a previously filed shelf registration statement with the SEC. SELLAS focuses on developing novel cancer therapies, including its lead candidate, GPS, targeting the WT1 protein found in various tumors, and a CDK9 inhibitor, GFH009.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is set to host a virtual event on January 31, 2023, at 8:30 a.m. EST, focusing on the treatment landscape for acute myeloid leukemia (AML) and its lead therapy, galinpepimut-S (GPS). The event will feature hematology oncology expert Omer Jamy, MD, who leads the Phase 3 REGAL study at the University of Alabama. GPS targets tumors overexpressing the WT1 antigen and is currently in a Phase 3 trial for AML patients in complete remission post second-line therapy. A live Q&A session will follow the presentation, providing insights into SELLAS's innovative cancer therapies.
SELLAS Life Sciences Group announces the appointment of Andrew Elnatan as Vice President, Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls (CMC) and Quality. With nearly 30 years of experience in regulatory affairs, particularly in oncology, Elnatan aims to strengthen SELLAS' leadership during critical development phases for its clinical programs galinpepimut-S (GPS) and GFH009. His prior success with drug approvals across various global bodies, including the FDA, positions him well to advance SELLAS' regulatory strategies and milestones.
SELLAS Life Sciences Group (NASDAQ: SLS) announced encouraging results from its dose-escalating Phase 1 trial of GFH009, a CDK9 inhibitor, showing a confirmed complete response (CR) in a patient with acute myeloid leukemia (AML). Notably, 97.6% of patients exhibited reduced CDK9 activity biomarkers. The trial, consisting of 57 heavily pretreated patients, reported no dose-limiting toxicities and improved neutrophil counts. These findings suggest GFH009's potential as a treatment for AML and lymphoma, marking a significant milestone in oncology therapeutics.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced that the Independent Data Monitoring Committee (IDMC) has recommended the continuation of the Phase 3 REGAL study for galinpepimut-S (GPS) in acute myeloid leukemia without modifications. The IDMC's assessment of unblinded data showed promising results, indicating patients live longer than expected. The primary endpoint focuses on overall survival. This recommendation underlines the integrity of the trial and the potential of GPS as a therapeutic option for AML patients.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) has announced that its CDK9 inhibitor, GFH009, will undergo evaluation in pediatric solid tumors and leukemia models, through the National Cancer Institute's PIVOT Program. This involves a two-phase research plan focusing on pharmacokinetics and efficacy testing. The program is backed by NCI grants and aims to enhance preclinical testing for pediatric cancer treatments. CEO Angelos Stergiou expressed optimism about GFH009's potential to demonstrate significant anti-tumor activity in these studies, paving the way for its clinical development in pediatric indications.
SELLAS Life Sciences Group (NASDAQ: SLS) announced promising preclinical results for GFH009, a CDK9 inhibitor, in treating small cell lung cancer (SCLC). In a study with NCI-H209 xenografts, GFH009 alone reduced tumor growth by 40.4%, while combining it with the PARP inhibitor olaparib led to a 72.3% decrease. These results bolster plans for GFH009 in an upcoming solid cancer trial. No significant safety concerns arose during the study, highlighting GFH009's potential as a novel treatment in personalized cancer therapy.
SELLAS Life Sciences Group announced its participation in the JMP Securities Hematology and Oncology Summit, a virtual investor conference set for December 6-7, 2022. The CEO, Angelos Stergiou, will host a fireside chat on December 7 at 3:20 p.m. ET. SELLAS is focused on developing innovative cancer therapies, including their lead product candidate, GPS, which targets the WT1 protein in various tumor types. The company is also working on GFH009, a selective CDK9 inhibitor.
SELLAS Life Sciences Group, Inc. (SLS) reported a cash position of $21.3 million as of September 30, 2022, along with its financial results for Q3 2022. The company is advancing its Phase 3 REGAL study of galinpepimut-S (GPS) for acute myeloid leukemia (AML) and exploring further developments in ovarian cancer treatments. Research and development (R&D) expenses were $4.3 million for Q3 2022, a slight decrease year-over-year. The net loss narrowed to $7.0 million for Q3 2022 compared to $7.1 million in Q3 2021, reflecting ongoing clinical advancements.